Sangamo Therapeutics (LTS:0R1D) Asset Impairment Charge : $100.79 Mil (TTM As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Sangamo Therapeutics Asset Impairment Charge?

Sangamo Therapeutics's Asset Impairment Charge for the three months ended in Mar. 2024 was $4.35 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2024 was $100.79 Mil.

Sangamo Therapeutics Asset Impairment Charge Historical Data

The historical data trend for Sangamo Therapeutics's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sangamo Therapeutics Asset Impairment Charge Chart

Sangamo Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Asset Impairment Charge

Get a 7-Day Free Trial

155.01

Sangamo Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Asset Impairment Charge	Get a 7-Day Free Trial															58.57	51.35	44.80	0.30	4.35

Sangamo Therapeutics Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $100.79 Mil.

Sangamo Therapeutics Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Sangamo Therapeutics's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Sangamo Therapeutics (LTS:0R1D) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sangamo Therapeutics Inc (LTS:0R1D) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

SGMO:USA GBY:Germany

Address

7000 Marina Boulevard, Brisbane, CA, USA, 94005

Website

https://www.sangamo.com

Sangamo Therapeutics Inc is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemophilia, Central Nervous System, HIV, Lysosomal Storage Disorders, and Hemoglobinopathies.

Sangamo Therapeutics (LTS:0R1D) Headlines

No Headlines